Table 1.
Demographic and clinical characteristics of early and advanced-stages NSCLC patients in PMC cohort
| N = 42 | Methylated | Unmethylated | p-value | |
|---|---|---|---|---|
| PMC cohort: early-stage | ||||
| Sex | ||||
| Female | 6 | 2 (33%) | 4 (67%) | 1.00 |
| Male | 36 | 13 (36%) | 23 (64%) | |
| Smoking status | ||||
| Current smoker | 25 | 9 (36%) | 16 (64%) | 0.88 |
| Former smoker | 13 | 5 (38%) | 8 (62%) | |
| Never smoker | 4 | 1 (25%) | 3 (75%) | |
| Tumor histologic type | ||||
| Adenocarcinoma | 24 | 10 (42%) | 14 (58%) | n.a |
| Squamous | 16 | 3 (19%) | 13 (81%) | |
| Others | 2 | 2 (100%) | 0 (0%) | |
| Stage | ||||
| IA | 2 | 0 (0%) | 2 (100%) | n.a |
| IB | 11 | 1 (9%) | 10 (91%) | |
| IIA | 3 | 0 (0%) | 3 (100%) | |
| IIB | 10 | 7 (70%) | 3 (30%) | |
| IIIA | 16 | 7 (44%) | 9 (56%) | |
| N = 31 | Methylated | Unmethylated | p-value | |
|---|---|---|---|---|
| PMC cohort: advanced-stage | ||||
| Sex | ||||
| Female | 8 | 6 (75%) | 2 (25%) | 0.67 |
| Male | 23 | 17 (74%) | 6 (26%) | |
| Smoking status | ||||
| Current smoker | 11 | 8 (73%) | 3 (27%) | 1.00 |
| Former smoker | 20 | 15 (75%) | 5 (25%) | |
| Tumor histologic type | ||||
| Adenocarcinoma | 15 | 12 (80%) | 3 (20%) | n.a |
| Squamous | 14 | 10 (71%) | 4 (29%) | |
| Others | 2 | 1 (50%) | 1 (50%) | |
| Stage | ||||
| IIIB | 15 | 11 (73%) | 4 (27%) | n.a |
| IIIC | 2 | 1 (50%) | 1 (50%) | |
| IV | 14 | 11 (79%) | 3 (21%) | |
| RECIST | ||||
| PR | 10 | 7 (70%) | 3 (30%) | n.a |
| SD | 7 | 5 (71%) | 2 (29%) | |
| PD | 6 | 6 (100%) | 0 (0%) | |
| n.a. | 8 | |||
MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST. It is not possible to calculate p value because of the number of cases in each group is insufficient
PR partial response, SD stable disease, PD disease progression, n.a. not available